Publicaciones en colaboración con investigadores/as de Hospital del Mar (13)

2024

  1. RET Fusion Testing in Patients With NSCLC: The RETING Study

    JTO Clinical and Research Reports, Vol. 5, Núm. 4

2019

  1. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study

    Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2120-2132

2017

  1. Reflections on the Implementation of Low-Dose Computed Tomography Screening in Individuals at High Risk of Lung Cancer in Spain

    Archivos de Bronconeumologia, Vol. 53, Núm. 10, pp. 568-573

2014

  1. Accurate identification of ALK positive lung carcinoma patients: Novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry

    PLoS ONE, Vol. 9, Núm. 9

2012

  1. Recommendations for the optimal management of early and advanced urothelial carcinoma

    Cancer Treatment Reviews, Vol. 38, Núm. 5, pp. 431-441

2010

  1. Treatment of cancer with oral drugs: A position statement by the Spanish Society of Medical Oncology (SEOM)

    Annals of Oncology

  2. Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: Focus on special populations

    Cancer and Metastasis Reviews, Vol. 29, Núm. SUPPL. 1

  3. Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma

    Cancer and Metastasis Reviews, Vol. 29, Núm. SUPPL. 1

2007

  1. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy

    Annals of Oncology, Vol. 18, Núm. 3, pp. 522-528

2003

  1. Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma

    Annals of Oncology, Vol. 14, Núm. 6, pp. 867-872

2002

  1. Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer

    British Journal of Cancer, Vol. 86, Núm. 3, pp. 326-330

  2. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine

    Cancer, Vol. 95, Núm. 4, pp. 751-757

2000

  1. Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer

    European Journal of Cancer, Vol. 36, Núm. SUPPL. 2, pp. 17-25